MX2022002711A - Nuevos inhibidores heterociclicos de monoacilglicerol lipasa (magl). - Google Patents
Nuevos inhibidores heterociclicos de monoacilglicerol lipasa (magl).Info
- Publication number
- MX2022002711A MX2022002711A MX2022002711A MX2022002711A MX2022002711A MX 2022002711 A MX2022002711 A MX 2022002711A MX 2022002711 A MX2022002711 A MX 2022002711A MX 2022002711 A MX2022002711 A MX 2022002711A MX 2022002711 A MX2022002711 A MX 2022002711A
- Authority
- MX
- Mexico
- Prior art keywords
- magl
- inhibitors
- new heterocyclic
- monoacylglycerol lipase
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención proporciona nuevos compuestos heterocíclicos, que son inhibidores de monoacilglicerol lipasa (MAGL) que tienen la fórmula general (I), en donde A, L1, X, m, n y R1 a R4 son como se describieron en la presente invención, composiciones que incluyen los compuestos, procesos de fabricación de los compuestos y métodos de uso de los compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19199108 | 2019-09-24 | ||
PCT/EP2020/076347 WO2021058445A1 (en) | 2019-09-24 | 2020-09-22 | New heterocyclic monoacylglycerol lipase (magl) inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022002711A true MX2022002711A (es) | 2022-03-22 |
Family
ID=68066569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022002711A MX2022002711A (es) | 2019-09-24 | 2020-09-22 | Nuevos inhibidores heterociclicos de monoacilglicerol lipasa (magl). |
Country Status (16)
Country | Link |
---|---|
US (1) | US20210094973A1 (es) |
EP (1) | EP4034538A1 (es) |
JP (1) | JP2022549446A (es) |
KR (1) | KR20220069003A (es) |
CN (1) | CN114401968A (es) |
AR (1) | AR120030A1 (es) |
AU (1) | AU2020354414A1 (es) |
BR (1) | BR112022005472A2 (es) |
CA (1) | CA3152213A1 (es) |
CO (1) | CO2022002000A2 (es) |
CR (1) | CR20220118A (es) |
IL (1) | IL289594A (es) |
MX (1) | MX2022002711A (es) |
PE (1) | PE20220710A1 (es) |
TW (1) | TW202126663A (es) |
WO (1) | WO2021058445A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
TW201936602A (zh) | 2017-11-28 | 2019-09-16 | 瑞士商赫孚孟拉羅股份公司 | 新雜環化合物 |
CN111566105A (zh) | 2018-01-08 | 2020-08-21 | 豪夫迈·罗氏有限公司 | 作为MAGL抑制剂的八氢吡啶并[1,2-α]吡嗪类化合物 |
EP3837263B1 (en) | 2018-08-13 | 2024-07-03 | F. Hoffmann-La Roche AG | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
CA3151516A1 (en) | 2019-09-12 | 2021-03-18 | F. Hoffmann-La Roche Ag | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |
CA3190277A1 (en) | 2020-09-03 | 2022-03-10 | Joerg Benz | Heterocyclic compounds |
AR128333A1 (es) * | 2022-01-25 | 2024-04-17 | Hoffmann La Roche | Nuevos compuestos heterociclicos |
WO2024088922A1 (en) * | 2022-10-24 | 2024-05-02 | F. Hoffmann-La Roche Ag | Heterocyclic compounds as inhibitors of monoacylglycerol lipase (magl) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
WO2011059118A1 (ko) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | 후각인지능력 검사 시스템 |
CA2862417C (en) * | 2012-01-06 | 2017-09-05 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
KR20180005250A (ko) | 2015-05-21 | 2018-01-15 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Pad4 억제제로서의 벤조이미다졸 유도체 |
CR20200416A (es) * | 2018-03-22 | 2020-10-26 | Hoffmann La Roche | Nuevos compuestos heterocíclicos |
EP3837263B1 (en) * | 2018-08-13 | 2024-07-03 | F. Hoffmann-La Roche AG | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
CR20210056A (es) * | 2018-08-13 | 2021-03-02 | Hoffmann La Roche | Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa |
-
2020
- 2020-09-22 CA CA3152213A patent/CA3152213A1/en active Pending
- 2020-09-22 EP EP20780981.5A patent/EP4034538A1/en active Pending
- 2020-09-22 KR KR1020227009452A patent/KR20220069003A/ko unknown
- 2020-09-22 AU AU2020354414A patent/AU2020354414A1/en active Pending
- 2020-09-22 AR ARP200102633A patent/AR120030A1/es unknown
- 2020-09-22 MX MX2022002711A patent/MX2022002711A/es unknown
- 2020-09-22 CN CN202080061840.2A patent/CN114401968A/zh active Pending
- 2020-09-22 JP JP2022518756A patent/JP2022549446A/ja active Pending
- 2020-09-22 CR CR20220118A patent/CR20220118A/es unknown
- 2020-09-22 US US17/027,976 patent/US20210094973A1/en not_active Abandoned
- 2020-09-22 WO PCT/EP2020/076347 patent/WO2021058445A1/en active Application Filing
- 2020-09-22 BR BR112022005472A patent/BR112022005472A2/pt not_active Application Discontinuation
- 2020-09-22 PE PE2022000299A patent/PE20220710A1/es unknown
- 2020-09-23 TW TW109132878A patent/TW202126663A/zh unknown
-
2022
- 2022-01-03 IL IL289594A patent/IL289594A/en unknown
- 2022-02-24 CO CONC2022/0002000A patent/CO2022002000A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4034538A1 (en) | 2022-08-03 |
JP2022549446A (ja) | 2022-11-25 |
AU2020354414A1 (en) | 2022-02-17 |
PE20220710A1 (es) | 2022-05-04 |
TW202126663A (zh) | 2021-07-16 |
AR120030A1 (es) | 2022-01-26 |
CR20220118A (es) | 2022-04-20 |
KR20220069003A (ko) | 2022-05-26 |
US20210094973A1 (en) | 2021-04-01 |
CO2022002000A2 (es) | 2022-04-08 |
BR112022005472A2 (pt) | 2022-06-14 |
CN114401968A (zh) | 2022-04-26 |
CA3152213A1 (en) | 2021-04-01 |
WO2021058445A1 (en) | 2021-04-01 |
IL289594A (en) | 2022-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20210077A (es) | Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa | |
PH12021500015A1 (en) | New heterocyclic compounds as monoacylglycerol lipase inhibitors | |
MX2022002711A (es) | Nuevos inhibidores heterociclicos de monoacilglicerol lipasa (magl). | |
CR20200416A (es) | Nuevos compuestos heterocíclicos | |
PH12021551167A1 (en) | New heterocyclic compounds | |
MX2022002311A (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl). | |
MX2022002554A (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl). | |
MX2022003023A (es) | Compuestos heterociclicos. | |
PH12019500664A1 (en) | New isoxazolyl ether derivatives as gaba a alpha5 pam | |
MX2022002831A (es) | Compuestos heterociclicos. | |
MX2022000243A (es) | Nuevos compuestos heterociclicos. | |
CR20230496A (es) | Compuestos heterocíclicos | |
MX2023002224A (es) | Compuestos heterociclicos. | |
MX2019013979A (es) | Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
MX2022011708A (es) | Derivados de benzodiazepinas como moduladores alostericos positivos (pam) de acido gamma-aminobutirico (gaba) a gamma1. | |
MX2023008634A (es) | Análogos de rapamicina y usos de estos. | |
MX342311B (es) | Nuevos compuestos de azaespirodecanona como inhibidores de lipasa sensible a hormonas (hsl). | |
BR112013028368A2 (pt) | novos compostos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona e octahidropiridinona | |
PH12021550320A1 (en) | Bicyclic heteroaryl derivatives |